cyrilzakka/clinical-trials huggingface dataset:
Urine NT-ProBNP in Neonatal Respiratory Distress

There is a need for a biochemical marker in addition to clinical condition which will help the physician to understand the clinical progress of the disease.

Urine Nt-proBNP, which does not need any blood sampling and can be collected easily, has not been evaluated for respiratory distress in newborn.

The investigators aim to evaluate the prognostic value of urine NT-proBNP in respiratory diseases in newborns by a controlled trial.

Neonatal diseases such as respiratory distress and transient tachypnea of newborn may require high level of intensive care. On the other hand, some minor difficulties in respiration can resolve within hours. Therefore, there is a need for a biochemical marker in addition to clinical condition which will help the physician to understand the clinical progress of the disease.

Serum NT-ProBNP level has been evaluated in transient tachypnea of newborn and found compatible with the clinical progress. Urine NT-proBNP has recently been evaluated in patent ductus arterioses and found compatible with the cardiac progress. However, urine Nt-proBNP, which does not need any blood sampling and can be collected easily, has not been evaluated for respiratory distress in newborn.

The investigators aim to evaluate the prognostic value of urine NT-proBNP in respiratory diseases in newborns by a controlled trial.

Eligibility Criteria:
Inclusion Criteria:

* study group; newborns who are admitted to the neonatal intensive care unit within first 2 days of life and have transient tachypnea of newborn or respiratory distress syndrome signed informed consent form
* Control Group: Newborns without any respiratory distress

Exclusion Criteria:

* any cardiac anomaly sepsis acute renal insufficiency syndromic cases low APGAR score at 5th minute (\<7) lung malformations no informed consent inability in collection of urine
Registry of Coronary Artery Ill Patients With Platelet Test Results

ONASSIST is a registry of coronary ill patients who have had a functional test measuring anti-platelet effect and/or a genetic profile of response to anti-platelet drugs.

The Onassist Project is an assistance for cardiologists that establishes an individual risk of stent thrombosis for each patient based on:

* a functional approach (evaluation of the antiplatelet effect of the antiplatelet regimen by multiple tests) and
* a pharmacogenomic approach (genetic profile of response to antiplatelet agents) It provides advices for specific therapeutics after identification of adverse drug interactions, treatment compliance issues and true genetic, functional or mixed resistance.

This individualized strategy allow to adjust the choice of the drugs and their optimal dosage considering the best benefit - risk ratio.

Follow up are regularly made to identify markers of MACE (major adverse cardiac event) or bleeding.

Eligibility Criteria:
Inclusion Criteria:

* coronary disease
* antiplatelets testing performed as part of usual care and / or gentic profile of antiplatelet response done

Exclusion Criteria:

* patient refusing to be part of the registry
The Intra-Drug Eluting Stent (DES) Restenosis Study

A Prospective, Randomized, Multi-Center Comparison of the Cypher Select™ Sirolimus-Eluting Stent and Balloon Re-Angioplasty for Treatment of Patients with Intra-Des Restenosis.

This is a prospective, randomized study to be conducted at up to 33 sites in France with 3 groups of patients (1 group with intra-Taxus™ restenosis, 1 group with intra-Cypher™ restenosis and 1 control group with intra-BMS restenosis). All patients will have a repeat angiography at 9 to 12 months post-procedure and will be followed up to 12 months post-procedure.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B\&C, I-II-III) OR patients with documented silent ischemia;
* Patient has an intra-DES (TAXUS™ OR CYPHER™) or intra-BMS restenosis of \>= 50% and \<100% (by QCA online of the MLD compared to the distal reference diameter) in a native coronary artery;
* Study target lesion must be located in a restenotic native coronary artery \>=2.25mm and \<=3.5mm in lumen diameter and \<=30mm in length by visual estimate and within a region up to 5mm to the proximal/distal stent edge;
* Study target lesion must have undergone coronary interventional treatment \>= 4 weeks previously. Patients with one ore more prior PTCA procedures at the target lesion are acceptable candidates.
* Study target lesion can not be located in a vessel containing another lesion requiring treatment. Lesions located in other vessels may be treated with percutaneous revascularization at the time of the procedure, BUT they must be successfully treated prior to the treatment of the study target lesion;
* Patient is candidate for a current percutaneous revascularisation technique;
* Patient is willing to comply with the specified follow-up evaluations (including angiographic follow-up);
* Patient must provide written informed consent prior to the procedure using a form that is approved by the local Ethics Committee;

Exclusion Criteria:

* Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented total CK \>2 times normal within the preceding 72 hours and the CK enzymes remain above normal at the time of treatment;
* Has unstable angina classified as Braunwald A I-II-III;
* Unprotected left main coronary disease with ³50% stenosis;
* Significant (\>50%) stenoses of additional lesions proximal or distal to the target lesion(s) that might require revascularization or impede runoff;
* Target lesion is in an internal mammary artery, saphenous vein bypass graft or is located in the left main or is ostial;
* Stent implantation(s) is a non-elective, emergency procedure;
* Stent at the target restenosed lesion is neither TAXUS™ , CYPHER™ DES nor a BMS;
* Documented left ventricular ejection fraction \<=25%;
* Totally occluded vessel (TIMI 0 level).
Prevalance of Temporomandibular Joint Disease

Temporomandibular joint (TMJ) disorders are common problems in the society and involve the masticator muscles, jaw joint and related structures. Since TMJ disorders affect functions such as eating and speaking, they can cause important problems in the daily life of the patient. Therefore, its diagnosis and treatment are of great importance. In the treatment of these patients, methods such as analgesic and anti-inflammatory drugs, splint, exercise, physical therapy modalities can be applied.

Although the prevalence of TMJ disease detected in the community is between 40-60%, the rate of symptoms or clinical findings was reported to be 87% in a study including 1040 people. Incomplete clarification of the etiology and pathogenesis, the lack of standard diagnostic and treatment approaches cause patients to learn to live with this problem, and severe pain and limitation of movement cause a decrease in quality of life and loss of workforce. Specific pathologies such as systemic inflammatory diseases, tumor, fracture, developmental anomaly cause temporomandibular joint diseases. It also causes a wider group of non-specific TMB originating from the musculoskeletal system.When the literature was reviewed, no publications on the frequency of TMJ joint disease were found in medical faculty students.

Eligibility Criteria:
Inclusion Criteria:

* Being a medical student
* Being between the ages of 18-35

Exclusion Criteria:

* Students who do not want to participate in the study
Burnout and Medical Errors in the Anaesthesiology Fraternity During Covid-19 Pandemic

We plan to perform an observational study to evaluate the prevalence of burnout, depression and medical errors in a designated exclusive Covid-19 patients hospital in Malaysia, during the Covid-19 pandemic. We also seek to assess the relationship between burnout and depression with medical errors. The population studied will be the anaesthesiology fraternity, who are at higher risk to the nature of their work at the frontlines of the pandemic.

During this unprecedented Covid-19 pandemic crisis in the whole world, Malaysia is also affected, with more than 5000 patients infected in the whole country as of 20th April, 2020. Many anaesthesiology clinicians, who are at the frontlines of managing Covid-19 patients, face increased workload, in addition to psychological stress from managing these patients, with stress also coming from being exposed to the risk of cross infection. Hence, they are possibly at high risk of burnout and depression. In such a time of increased stress, we also seek to find out the prevalence of medical errors by anaesthetic clinicians during this pandemic, and whether the medical errors are associated with burnout. Factors associated with burnout, depression and medical errors will also be evaluated.

Eligibility Criteria:
Inclusion criteria

1. All anaesthesiologists and anaesthesiology medical officers currently serving in the Department of Anaesthesiology and Intensive Care, Sungai Buloh Hospital

Exclusion criteria

1. Subjects who refuse to participate
2. Subjects working in Department of Anaesthesiology and Intensive Care, Sungai Buloh Hospital, for less than 1 month
Effect Of Intravenous Iron Versus Placebo On Muscle Oxidative Capacity And Physical Performance in Premenopausal Women

Effect of intravenous iron substitution (iron carboxymaltose (Ferinject®), total dose 15 mg/ kg (maximal dose: 1000mg) in 250 ml 0.9 % NaCl; intravenous infusion in 20 min)in non-anemic premenopausal women with iron deficiency on

Primary objective:

- Mitochondrial capacity (Phosphocreatine Recovery rate assessed by 31P-MR-spectroscopy of the lower leg muscle)

Secondary objectives:

* Maximal oxygen uptake during a graded cycling exercise test and time to exhaustion at submaximal power during a constant-load cycling exercise test
* Plantarflexor muscle fatiguability as assessed by isokinetic dynamometry
* Trial with medicinal product


Eligibility Criteria:
Inclusion criteria: INCLUSION CRITERIA

* Healthy female subjects, Age \> 18 years, premenopausal, regularly menstruating
* BMI 18-25 kg/m2.
* Serum ferritin level \< 15ug/ml
* Recreationally active with = 1.5 h/w structured activity
* Adequate contraception during the study period
* Informed consent

Exclusion criteria: EXCLUSION CRITERIA

* Anemia with Hb level \< 120 g/l
* Known hypersensitivity to iron carboxymaltose, iron sucrose or iron sulfate
* Intake of iron preparations (also multivitamins containing iron) during the last 8 weeks before the start of the trial protocol
* Pregnancy or lactation
* Any cardiovascular or pulmonary disease
* Any orthopaedic or rheumatologic disease which affects exercise performance
* Presence of muscle disease
* Acute or chronic infection/inflammation or malignancy
* Known mental disorders (e.g. depression)
* Intake of concurrent medication, except oral contraceptives
* CRP \> 10 mg/l
* TSH out of normal range
* Elevated CK (\> 167 U/l)
* Any concurrent medical condition(s) that, in the view of the investigator, would prevent compliance or participation or jeopardize the health of the patients.
* Participation in any other therapeutic trial within the previous month
A Study to Assess the Effect of My Happy Flo on Alleviating Period Symptoms and Heavy Flows.

This clinical study aims to evaluate the effectiveness of My Happy Flo, a dietary supplement, in alleviating period symptoms and heavy menstrual flows. The study involves 40 participants, who will take the supplement daily for three menstrual cycles. Primary outcomes, such as the severity of heavy flows, prolonged periods, cramps, mood, energy levels, cycle regulation, and fatigue, will be measured using validated questionnaires completed after each menstrual cycle. Secondary outcomes, including Vitamin D and Iron levels, will be assessed through blood tests at the beginning and end of the study period.


Eligibility Criteria:
Inclusion Criteria:

* Female, aged 18 or over
* Experiencing heavy period flows
* Two or more self-reported symptoms (prolonged periods, cramps, poor mood, fatigue, irregular cycle)
* Signs of potential anemia or iron deficiency
* No known allergies to the product ingredients
* Willing to comply with study requirements and limit caffeine intake
* Generally healthy - do not live with any uncontrolled chronic disease

Exclusion Criteria:

* Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders
* A diagnosis of sports anemia within the previous 6 months
* Anyone with known severe allergic reactions that require an Epi-Pen
* Women who are pregnant, breastfeeding, or trying to conceive
* Anyone unwilling to follow the study protocol
* Anyone who has undergone any surgeries or invasive treatments (such as immunotherapy, chemotherapy, radiation, or biological cancer) in the last 30 days or has any planned for the next 12 weeks
* Anyone with a history of substance abuse
* Anyone currently participating or planning to participate in a research study
* Anyone taking prescription anticonvulsants (anti-seizure medications)
* Anyone taking prescription anticoagulant medications (blood thinners)
* Anyone taking any hormone-modulating medications (e.g., hormonal birth control, hormone replacement therapy, testosterone, tamoxifen, thyroid medications, etc.)
* History of hysterectomy, oophorectomy, or other surgery to the reproductive organs
* History of gynecologic cancer, such as cervical, ovarian, uterine, vaginal, or vulvar cancer
* Currently experiencing menopausal or perimenopausal symptoms
* Changes or cessation of hormonal birth control in the last three months
* Active or abnormal uterine/vaginal bleeding
* Resides in RI, NY, NJ, or AZ
Effect of Intraoperative Dexmedetomidine on Lung Protection Following Thoracic Aorta Surgery With Hypothermic Circulatory Arrest: a Randomized Clinical Trial

Dexmedetomidine has been known to protect the lung against inflammation and oxidative stress in diverse clinical settings. The investigators aimed to investigate the lung protective effect of dexmedetomidine in patients undergoing thoracic aortic surgery with hypothermic circulatory arrest, which is associated with systemic inflammatory response, and oxidative stress.

Patients will be divided into 2 groups; dexmedetomidine group and control group. Dexmedetomidine group will receive dexmedetomidine during and after thoracic artery surgery. And control group will receive the same amount of normal saline instead. Analyzing patients lung function and serum factors, which indicates the degree of systemic inflammatory responses and oxidative stress, The investigators will investigate the protective effect of dexmedetomidine on lung.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing thoracic aorta surgery with hypothermic circulatory arrest, over 20-of age

Exclusion Criteria:

* Unstable vital sign before surgery
* Severe pulmonary disease requiring consistent treatment
* Illiterate
* Pregnancy
Treatment of Early Childhood Caries Using Silver Diammine Fluoride and Sodium Fluoride Tricalciumphosphate and the Effects on Oral Health Related Quality of Life

There is still a need for the assessment of different minimal intervention strategies and treatments focusing on the prevention and arrest of carious lesions of primary molars The evidence-based clinical practice guideline on non-restorative treatments for cavitated carious lesions advocate the use of silver diammine fluoride biannually for high caries risk patients

Although SDF has been proven to be highly effective in carious lesion arrest and prevention, the staining effect, metallic taste due to silver content and the minimal mucosal irritation have been noted as primary cause of disinterest among clinicians in the use of this material.

The use of NaF-fTCP as a caries preventive material has not been studied widely. The importance of oral hygiene education and diet modification to achieve an effective caries control has been widely discussed. The off-label use of NaF-fTCP as a caries arresting agent has not been studied on primary dentition. There is a dearth of evidence regarding the effectiveness of NaF-fTCP towards caries arrest and prevention in pragmatic settings.

A comparison between the SDF and NaF-fTCP application on the cavitated carious primary molars and their effect on the oral health-related quality of life of the children has not been published in the literature.

Eligibility Criteria:
Inclusion criteria:

Children will be invited to participate in the trial if they fulfil the entire selection criteria as described below:

* 4 to 6 years-of-age
* Identification of one or more carious primary molars without involvement of the pulp confirmed by bitewing radiographs
* Up to three teeth per each participant will be selected for intervention
* Has normal salivary flow rate
* Does not consume medications regularly for any medical condition
* Has not or will not receive any fluoride therapy or relevant dental therapy from other dental sources within the last six months

Exclusion criteria:

Children will be excluded from the trial if they fulfil any of the following criteria:

* Presence of any pain, ulceration, fistula/sinus or an abscess
* Premature hypermobility of carious teeth which can be potentially included in the study
* History of allergy to any product containing silver compounds
* Siblings of the participants will not be allowed to participate to ensure any chance of ECOHIS duplication.
Verification of Alternative Do-it-yourself Equipment Respirators for the COVID-19 Personal Protective Equipment (PPE)

The COVID-19 pandemic health crisis forces health institutions to lower their standards of protection as supplies of personal protective equipment decrease despite the safety of front-line workers worldwide . This shortage specifically affects high-quality protective masks, such as those called FFP2. As alternatives, we offer a reusable mask based on a ventilation mask combined with a breathing filter for anesthesia breathing circuits. The purpose of the study is to assess the sealing potential of this mask in the field and possibly prove a non-inferior sealing compared to standard masks type FFP2.

The ongoing 2020 COVID-19 pandemic challenges healthcare providers (HCP) worldwide with a rapid consumption and shortage of personal protection equipment (PPE), especially high-level filtration respirator masks. Respirators used by HCPs are mainly single use face filtering pieces with at least level P2 protection for single shift use following European EN 149 standards defining protection level against hazardous particles.

In response to the risk of shortage we propose a novel reusable do-it-yourself (DIY) respirator assembled with already widely available components in hospital stocks: a standard breathing filter plugged in an anaesthesia facial mask held in place with a hook ring strapped to a silicone head harness. As reports of a modified full-face snorkelling (MFS) mask used for non-invasive ventilation in infected patients emerged in Italy, we reckon that it could also be used as PPE with a modified valve and breathing filter.

Eligibility Criteria:
Inclusion Criteria:

* adult volunteers working in a first line healthcare service with basic knowledge of donning PPE including respirators
* 5 females and 5 males

Exclusion Criteria:

* smoking or unhealthy participants with respiratory affections to avoid breathing difficulties during testing
* any known allergy towards medical silicone or any other material of each component and ingredients used for disinfection of the test area and material between participants
Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6

This multi-center, post-marketing, observational study evaluates the real world safety and effectiveness of glecaprevir plus pibrentasvir use in participants infected with the hepatitis C virus genotype 1 - 6.


Eligibility Criteria:
Inclusion Criteria:

* Patients with chronic hepatitis C virus infection and administering glecaprevir plus pibrentasvir.

Exclusion Criteria:

* Patients previously treated with glecaprevir plus pibrentasvir.
Resident Training Enhanced by New Innovations: Teleintubation

The overall goal of this study was to create a simulation environment with repeated practice for residents and intense, immediate feedback. Repeated simulations for neonatal resuscitation when coupled with clinical experience have been shown to improve resident confidence.The investigators sought to determine if resident exposure to individual training and video laryngoscopy using the C-MAC video laryngoscope would improve cognitive skills and decrease intubation times in a neonatal manikin. The primary outcome was time to intubation after one year. The secondary outcome was the ability to retain cognitive instruction related to intubation

Objective: Tracheal intubation of infants and children is a critical lifesaving skill, but many upper level pediatric residents are unable to successfully intubate neonates or pediatric patients in a timely manner. Simulation has been shown to be effective in teaching procedural skills, but it is not known if improvements in intubation skills can persist. The investigators sought to determine if video laryngoscopy could be used to enhance resident intubation skills that would be retained for one year.

Methods: There were 67 Pediatric and Internal Medicine/Pediatric residents, levels 1-4, who completed the study and were randomized by month of service into non-intervention (NI, n= 36) and intervention (IN, n=31) groups. IN residents observed the intubation portion of the Neonatal Resuscitation Program (NRP) training video and received cognitive instruction and 30 minutes of hands on instruction using a video laryngoscope. At the study's conclusion, 12 months after enrollment, residents completed a survey of intubations of live patients over the past year, a cognitive assessment of intubation, and were timed on intubating a manikin. Results were analyzed by Student's T-Test.

Eligibility Criteria:
Inclusion criteria:

* Pediatric residents

Exclusion criteria:

* Residents from other departments
* Neonatology fellows
* Medical students
* Medical school Faculty
An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease

The primary purpose of this study is to confirm the clinical efficacy and mechanism of action of GV-971, and identify incidence of known adverse reactions in long-term use and observe new adverse reactions, providing more guidance for clinical use.


Eligibility Criteria:
Inclusion Criteria:

* Mild to moderate AD per NIA-AA.
* History of cognitive and functional decline over at least 1 year.
* MMSE scores between 11 and 24 (inclusive) at baseline.
* Hachinski Ischemic Score (HIS) scale total score ≤ 4.
* Hamilton Rating Scale for Depression/17 items (HAMD) total score ≤ 10.
* Brain MRI scan show the highest possibility of AD.
* Have a reliable study partner/caregiver.
* Sign the informed consent form.

Exclusion Criteria:

* Diagnosis of a dementia-related central nervous system disease other than AD.
* Major structural brain disease as judged by MRI.
* A resting heart rate of \< 50 beats per minute (bpm) after 10 minutes of rest.
* Major medical illness or unstable medical condition within 12 months of screening.
* Concomitant use of donepezil, rivastigmine, galanthamine, huperzine A, memantine, or aducanumab within 6 moinths prior to baseline.
* Inadequate hepatic function.
* Inadequate organ function.
* ECG clinically significant abnormalities.